We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Emerging co-resistance to first and second line antibiotics in urinary pathogens and implications for the control of urosepsis.

Project Code

MRCIIAR25Br Avison 

Research Theme

Infection, Immunity, Antimicrobial Resistance and Repai

Project Summary Download

MRCIIAR25Br AvisonDownload

Summary

Reducing antibiotic resistance (ABR) among urosepsis pathogens – derived from urinary tract infection (UTI) via pyelonephritis – is central to the UKs ABR-reduction strategy. This PhD is based within an inter-disciplinary consortium aiming to reduce trimethoprim use for UTI by promoting  switching to an alternative first-line antibiotic. This may reduce resistance to second-line UTI/pyelonephritis and urosepsis therapies among UTI pathogens, reducing hospital admissions and saving lives. You will use genomic epidemiology and functional genomics to identify and explain links between resistance to several alternative first-line, second-line and urosepsis therapies with findings helping the consortium to inform UK antibiotic prescribing policy.

Lead Supervisor

Professor Matthew Avison

Lead Supervisor Email

bimba@bristol.ac.uk

University Affiliation

Bristol